Merck and Moderna maintain a decade-old 50/50 collaboration on the personalized mRNA cancer vaccine intismeran autogene, which delivered statistically significant Phase 3 melanoma data in August 2026 and drove sharp share-price gains without any indication of a broader corporate combination. Moderna has independently raised $2.6 billion via convertible notes in September to fund its oncology pipeline, while Merck has pursued separate acquisitions such as Terns Pharmaceuticals for $6.7 billion earlier in the year to diversify ahead of Keytruda patent expirations. With only three months remaining in 2026 and no regulatory filings, board discussions, or analyst speculation pointing to a full merger, market-implied odds reflect the low probability of an announcement. Tail risks remain limited to an abrupt strategic pivot, though current capital structures and pipeline momentum make such a shift improbable.